Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients With Advanced Malignancies
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the side effects and best dose of selinexor when given together
with several different standard chemotherapy or immunotherapy regimens in treating patients
with malignancies that have spread to other places in the body and usually cannot be cured or
controlled with treatment (advanced). Selinexor may stop the growth of cancer cells by
blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to
stop the growth of cancer cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Studying selinexor with different standard chemotherapy
or immunotherapy regimens may help doctors learn the side effects and best dose of selinexor
that can be given with different types of treatments in one study.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Karyopharm Therapeutics, Inc National Cancer Institute (NCI)